Published in Osteoporos Int on January 01, 2001
How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. Can Fam Physician (2003) 2.42
Knowledge and awareness about osteoporosis and its related factors among rural Turkish women. Clin Rheumatol (2007) 1.04
Development and validation of the osteoporosis prescreening risk assessment (OPERA) tool to facilitate identification of women likely to have low bone density. Clin Rheumatol (2004) 0.93
Awareness of osteoporotic patients. Osteoporos Int (2004) 0.87
Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture. Rheumatol Int (2012) 0.83
Osteoporosis: are healthcare professionals missing an opportunity. Springerplus (2013) 0.76
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Fix what's wrong, not what's right, with general practice in Britain. BMJ (2000) 7.16
Socio-economic status of the patient and doctor-patient communication: does it make a difference? Patient Educ Couns (2005) 3.40
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med (1998) 2.14
A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int (2001) 2.06
Influence of the presence of doctors-in-training on the blood pressure of patients: a randomised controlled trial in 22 teaching practices. J Hum Hypertens (2004) 1.99
Wet combing for head lice: feasibility in mass screening, treatment preference and outcome. J R Soc Med (2002) 1.82
Attitudes to risk taking in medical decision making among British, Dutch and Belgian general practitioners. Br J Gen Pract (1990) 1.73
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Nitric oxide downregulates interleukin 1beta (IL-1beta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes. J Rheumatol (1998) 1.55
Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43
Rheumatic and musculoskeletal diseases and impaired quality of life: a challenge for rheumatologists. J Rheumatol (1996) 1.42
[Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate]. Gynecol Obstet Fertil (2003) 1.40
Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage (2007) 1.26
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 1.19
Use of blood tests in general practice: a collaborative study in eight European countries. Eurosentinel Study Group. Br J Gen Pract (1995) 1.17
Social support and health-related quality of life in hip and knee osteoarthritis. Qual Life Res (2004) 1.17
Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal Osteosonogrammetry Study Group. J Bone Miner Res (2000) 1.13
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int (2009) 1.13
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab (2000) 1.10
Tools in the assessment of sarcopenia. Calcif Tissue Int (2013) 1.09
Strontium ranelate increases cartilage matrix formation. J Bone Miner Res (2001) 1.08
The role of calcium and vitamin D in the management of osteoporosis. Bone (2007) 1.06
Impact of the transition from a conventional to an integrated contextual medical curriculum on students' learning patterns: a longitudinal study. Med Teach (2009) 1.06
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.06
Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol (2004) 1.05
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int (2012) 1.05
Is GP-patient communication related to their perceptions of illness severity, coping and social support? Soc Sci Med (2002) 1.04
Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage (1996) 1.02
Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas (1997) 1.00
Reactive oxygen species downregulate the expression of pro-inflammatory genes by human chondrocytes. Inflamm Res (2003) 1.00
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecol Endocrinol (2002) 0.99
Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage (2001) 0.99
Paget's disease of bone: diagnosis and management. BMJ (1996) 0.98
Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int (1995) 0.97
On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center. Rheumatology (Oxford) (2001) 0.96
Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int (2006) 0.96
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int (2013) 0.95
What is the role of quality circles in strategies to optimise antibiotic prescribing? A pragmatic cluster-randomised controlled trial in primary care. Qual Saf Health Care (2007) 0.95
Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol (2001) 0.94
Which bacteria are found in Belgian women with uncomplicated urinary tract infections in primary health care, and what is their susceptibility pattern anno 95-96? Acta Clin Belg (1998) 0.94
European regulatory perspectives for innovative therapies. Osteoporos Int (2008) 0.93
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int (1998) 0.92
Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels. Aging Clin Exp Res (2002) 0.92
Genetic markers of osteoarticular disorders: facts and hopes. Arthritis Res (2001) 0.91
Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol (1998) 0.90
The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int (2002) 0.89
Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium. Bone (2001) 0.87
First-generation versus third-generation comprehensive geriatric assessment instruments in the acute hospital setting: a comparison of the Minimum Geriatric Screening Tools (MGST) and the interRAI Acute Care (interRAI AC). J Nutr Health Aging (2011) 0.87
The potential of the inventory of learning styles to study students' learning patterns in three types of medical curricula. Med Teach (2008) 0.87
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int (1997) 0.87
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int (2003) 0.87
[A FRAX model for the assessment of fracture probability in Belgium]. Rev Med Liege (2009) 0.86
A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res (2001) 0.86
Effects of etodolac on human chondrocytes cultivated in three dimensional culture. Clin Rheumatol (1989) 0.86
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 0.85
Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Franco-Belgian Task Force. Rev Rhum Engl Ed (1997) 0.85
Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics (1999) 0.85
Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ (2001) 0.85
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum (1995) 0.85
Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol (1985) 0.85
The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits. J Clin Densitom (1999) 0.84
Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int (2012) 0.84
Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture. Rheumatol Int (2012) 0.83
Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage (2000) 0.83
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int (2009) 0.83
Fractures in osteoporosis: the challenge for the new millennium. Osteoporos Int (2005) 0.82
Genetics of menopause-associated diseases. Maturitas (2001) 0.82
Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain. Clin Exp Rheumatol (2004) 0.82
Assessment of determinants for osteoporosis in elderly men. Osteoporos Int (2008) 0.82
In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radic Res (2000) 0.82
Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis. Calcif Tissue Int (1996) 0.81
[Treatment of Paget's disease with low dose sodium etidronate (5mg/kg/day). Occurrence of reversible transient suspected leukopenia]. Rev Rhum Mal Osteoartic (1985) 0.81
The development of a European questionnaire for quality of life in patients with vertebral osteoporosis. Scand J Rheumatol Suppl (1996) 0.81
High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: a plausible role of increased parathyroid hormone secretion. Osteoporos Int (1999) 0.80
Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women. Bone (2012) 0.80
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone (2006) 0.80
Loading and skeletal development and maintenance. J Osteoporos (2010) 0.80
Parathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women. Osteoporos Int (1998) 0.80
Anabolic events in osteoarthritis. Osteoarthritis Cartilage (1999) 0.80
Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis (2000) 0.80
Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors. Calcif Tissue Int (1999) 0.79
Acute changes in serum calcium and parathyroid hormone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers. Clin Rheumatol (1997) 0.79
Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract (2010) 0.79
Interest of a prescreening questionnaire to reduce the cost of bone densitometry. Osteoporos Int (2002) 0.79
Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Invest (1997) 0.78
[The behavioral determinants for health centers in health districts of urban Africa: results of a survey of households in Kinshasa, Congo]. Trop Med Int Health (2000) 0.78